PARIS, August 31, 2017 /PRNewswire/ --
Valneva SE, a leading European biotech company specializing in innovative vaccines, reports earnings for the first half of 2017. Thomas Lingelbach, President & CEO of Valneva, comments on the results and the Group's evolution.
Watch video interview and read transcript:
Topics covered in the interview include:
- H1 results
- Main sources of revenue
- Clinical vaccine portfolio
- Company evolution
About Valneva SE
Valneva is a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva's portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).
Valneva shares are tradable on Euronext-Paris, the Vienna stock exchange and Deutsche Börse's electronic platform Xetra®. The Company has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at http://www.valneva.com .